Skip to content

‘Client satisfaction’ – guidelines for assessing the quality of leprosy services from the clients’ perspective

M. van Dijk, J. Visschedijk, Anke van der Kwaak
Publication year

Every year, over half a million new leprosy are detected. Since there is no evidence that the transmission in high endemic countries has been substantially interrupted, it is expected that in the coming years considerable numbers of leprosy patients will continue to report to health facilities.

Related work

  • Long Term Collaboration with Netherlands Leprosy Relief

    • Institute
    • Project

    In a long-term collaboration, KIT Royal Tropical Institute and the Netherlands Leprosy Relief (NLR) have been working to reduce leprosy, whilst improving methods for its evaluation and study. This has resulted in significant research contribution and global policy setting, as well as country-level improvements in leprosy detection and control. Furthering the agenda in global leprosy […]

  • Risk factors for participation restriction in leprosy and development of a screening tool to identify individuals at risk

    • Institute
    • Publication

    The World Health Organization International Classification of Functioning, Disability and Health defines participation as involvement in a life situation. Participation restrictions may occur in any life situation across nine areas of activity and participation. These are learning and applying knowledge, general tasks and demands, communication, mobility, self-care, domestic life, inter-personal interactions and relationships, major life […]

  • Partnership for sustainable leprosy control beyond 2005

    • Institute
    • Publication

    Partnerships have always played an important role in leprosy control. The World Health Organization (WHO) and national and international non-governmental organizations (NGOs) provide a significant supportive function in partnership with national governments. Among the NGOs involved, the members of the Federation of Anti-Leprosy Associations (ILEP), The Nippon Foundation, Novartis and the World Bank have played […]